This episodes discusses the pragmatic realities of conducting post-market surveillance for AI medical devices. It features a conversation with Dr Dan Mullarkey, Medical Director at Skin Analytics, a company specialising in AI for skin cancer detection. In our conversation you’ll hear Dan explain how Skin Analytics have tackled some difficult questions such as: How do you decide the appropriate sensitivity levels of an AI device? How you can ensure you’re given access to the ongoing outcome data you need from NHS organisations to conduct appropriate PMS  What are the challenges of dealing with real world data analysis compared to traditional research approaches?